

Pfizer-BioNTech COVID-19 Vaccine Information Sheet for Student Immunization (ages 5-17)

Taiwan Centers for Disease Control, Ministry of Health and Welfare, June 14, 2022

Dear parents/guardians:

COVID-19 vaccination can protect children from symptomatic infection, severe disease, complications, or death from COVID-19. Please read the following information, fill in the consent form, and return it to the school, public health sectors, or medical care providers. Thank you for your support and cooperation.

Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine is a messenger RNA (mRNA) vaccine that encodes the SARS-CoV-2 virus spike(S) protein. This vaccine has received an emergency use authorization in markets including the United States, the European Union, and Taiwan.

- ◆ **Age indication:** Pfizer-BioNTech COVID-19 Vaccine is approved in Taiwan for use as a **two-dose primary series for children 5 years of age and older** and as a **single booster dose for individuals 12 years of age and older**.
- ◆ **Dosage and administration interval of primary vaccination courses:**

The Advisory Committee on Immunization Practices (ACIP) of the Ministry of Health and Welfare in Taiwan recommends administering 2-dose primary series of BNT162b2/Comirnaty separated by at least four weeks (28 days). **An interval of at least 4 to 8 weeks between the first and second dose is recommended for children 5 to 11 years of age. Because an extended vaccine interval may boost immune response and possibly reduce the risk of the rare adverse event of myocarditis or pericarditis after mRNA vaccination, in principle, an interval of 12 weeks between the first and second dose is recommended for children 12 to 17 years of age.**

 - **For children aged 5 to 11 years (orange cap/Comirnaty): 0.2 mL per dose (dilute before use, 10 µg mRNA/dose)**
 - **For individuals aged 12 years and older (purple cap/BNT162b2): 0.3 mL per dose (dilute before use, 30 µg mRNA/dose)**
- **Booster dose:**

Taiwan ACIP recommends a booster vaccination with the **30 µg BNT162b2 (purple cap) COVID-19 vaccine** for adolescents **aged 12 to 17 years, from 5 months after receiving their last primary dose.**
- ◆ **Safety and protective efficacy:**
 - This vaccine does not contain replication-competent SARS-CoV-2 viral particles and cannot cause the recipient to become infected with COVID-19.
 - Clinical trial (mostly non-omicron variants) results show that for individuals aged ≥ 16 years, this vaccine is about 94.6% effective at preventing symptomatic COVID-19 infection at least seven days after the second dose. For adolescents aged 12 to 15 years, the vaccine's efficacy in preventing symptomatic infection is nearly 100%. For adolescents aged 5 to 11 years old, the vaccine's efficacy in preventing symptomatic infection is nearly 90.7%¹.

Before vaccination: contraindications and precautions

Contraindications to vaccination:

This vaccine must not be given to individuals with a history of severe allergic reactions to any of the vaccine components, or who had a severe allergic reaction to the first dose.

Precautions:

1. **This vaccine and other vaccines could be administered at the same time on different arm or administered at any interval.**
2. Vaccination should be postponed for individuals suffering from a fever or an acute moderate-to-severe illness.
3. Individuals with a weakened immune system, or who are taking medicines that weaken the immune system, may have a diminished immune response to the vaccine. (There is no data to assess administration on those who are immunocompromised or receiving immunosuppressive therapy.)
4. There is a lack of clinical trial data and safety information on COVID-19 vaccination for pregnant women. Observational studies show that pregnant women have a higher risk of developing severe symptoms if they are infected by SARS-CoV-2. Pregnant women at high risk of occupational exposure to SARS-CoV-2, or who

have chronic diseases that increase their risk of severe illness, should weigh the risks and benefits of inoculation with their doctor before receiving the vaccine.

5. Vaccination is advised for lactating women who are part of a recommended group for vaccination (such as medical staff). There is not enough data to assess the safety of COVID-19 vaccines for lactating women or on the effects on nursing children. However, COVID-19 vaccines are generally considered safe. Women can continue to breastfeed after receiving a COVID-19 vaccine.

After vaccination: precautions and possible side effect

1. To ensure that medical treatment is available in the very rare event of a severe and sudden allergic reaction, **individuals should be observed at or near the vaccination site for at least 15 minutes after inoculation. Recipients should closely self-monitor for reactions in the 15 minutes after leaving the vaccination site.** People with a history of acute allergic reactions after a vaccine or other injection should remain at the vaccination site for at least 30 minutes after inoculation. Recipients who are taking antiplatelet and anticoagulant drugs, or who suffer from abnormal blood coagulation, should apply pressure on the injection site for at least two minutes after the injection and observe for persistent bleeding or hematoma.

2. Fainting after vaccination

Fainting is usually triggered by pain or anxiety. Sometimes people faint after vaccination, **especially adolescents. Symptoms like vertigo and nausea typically occur during or immediately after injection (within five minutes).** During mass vaccination, there is occasionally the collective occurrence of post-vaccination fainting in recipients. This phenomenon is categorized as a mass psychogenic illness. Scientific evidence shows that fainting is due to the vaccination process but not to the vaccines themselves. Vaccine recipients are advised **to not get vaccinated on an empty stomach, to avoid longer waiting times at vaccination sites, and to relax while waiting in line by listening to music, watching videos, or talking. Recipients should be in a seated position when receiving a vaccine and during the post-vaccination observation period,** to prevent falls and injuries if fainting occurs. **Recipients who faint after vaccination should be monitored by medical personnel until regaining consciousness, and should be asked to sit or lie down in the observation area and provided emotional support by medical personnel. If a recipient does not recover immediately, medical personnel should provide further care and inquire about the patient's medical history.**

3. Possible side effects after vaccination

- The most common side effects that occur after vaccination are **pain, redness, and swelling at the injection site, which usually go away within several days. Other possible reactions include fatigue, headache, muscle ache, elevated body temperature, chills, joint pain, and nausea.** The frequency of experiencing these side effects decreases with increasing age, and most reactions are mild and disappear within a few days. Clinical trials show that side effects are **more common after the second dose compared to the first. It is common to develop a fever ($\geq 38^{\circ}\text{C}$) after vaccination. This usually goes away within 48 hours.**
- Rare and mostly mild cases of myocarditis and pericarditis have been observed in adolescents after vaccination with the mRNA COVID-19 vaccines, according to both the World Health Organization's Global Advisory Committee on Vaccine Safety (GACVS)² and Taiwan's ACIP recommend. **Seek medical attention for your child immediately if symptoms of myocarditis or pericarditis occur within 28 days after vaccination. These symptoms include chest pain, pressure, or discomfort; palpitations (a heartbeat that feels irregular, fluttery, or as if it is skipping a beat); syncope (fainting), shortness of breath; exercise intolerance (for example, becoming out of breath after walking a few steps or being unable to climb stairs). Inform the doctor of your child's vaccination history.** Clinicians will need to rule out other potential causes of myocarditis and pericarditis, which include SARS-CoV-2 infection, other viral infections and conditions.
- The prognosis for such cases of myocarditis and pericarditis is mainly favorable. Cases mostly occur within 14 days after vaccination. They occur more commonly after the second dose than the first, and more commonly in males aged 40 and younger than in women or men in other age groups. In addition, some studies have preliminarily confirmed that a longer interval between the first dose and second dose may reduce the risk of myocarditis or pericarditis. In the UK and US, the recommended interval between the first and second dose has been changed to 8 weeks or 12 weeks for adolescents or young men under 40³⁻⁴. The recommended interval of a two-dose mRNA vaccine for adolescents in Taiwan is in line with this new guidance.
- After SARS-CoV-2 infection, there is the risk of severe COVID-19 symptoms or the complication of myocarditis. During a pandemic, this risk must be considered alongside the extremely low likelihood of developing myocarditis or pericarditis after vaccination. Due to the COVID-19 pandemic and the threat of mutant strains, a second dose of

the COVID-19 Vaccine is approved for adolescents who had no severe adverse reactions to the first dose. Only the individual can decide whether to take the second dose, based on a physician's assessment and objective factors, such as underlying medical conditions, risk factors for severe illness, proximity of residence to infection hotspots, and the need to enter infection hotspots. Your child can choose to be vaccinated at school or at a medical institution.

- Results of VAERS surveillance show that the reporting rate of myocarditis or pericarditis after mRNA vaccination in Taiwan is similar to that observed by international vaccine safety surveillance. The U.S., Canada, Japan, and other countries have monitored the reporting rate of myocarditis or pericarditis among younger people after mRNA vaccination (Moderna or Pfizer-BioNTech) and found that such rare adverse events occurred more commonly after the second dose than the first dose. Some observational studies of post-marketing data⁵ suggest that there may be an increased risk of myocarditis and pericarditis in males under 40 years of age following the second dose of the Moderna COVID-19 Vaccine relative to other authorized or approved mRNA COVID-19 vaccines. But the comparative analysis of the risk of myocarditis or pericarditis following vaccination with the Moderna vaccine and Pfizer-BioNTech vaccine has not yet yielded fully consistent results⁶.
 - According to the US' safety monitoring data, the reporting rate of myocarditis or pericarditis among children aged 5-11 after receipt of the first dose of the Pfizer-BioNTech vaccine was 0 cases per million doses administered, and the reporting rates following the second dose were 2.0(females) and 4.3(males) cases per million doses administered⁷. According to the Australian vaccine safety monitoring data, the reporting rates of myocarditis or pericarditis for adolescents aged 5 to 11 years after either dose of the primary series were 1 (females) and 1 (males) cases per million doses administered ; the reporting rates following the second dose were 0 (females) and 2 (males) cases per million⁸.
 - The US safety monitoring data showed that the reporting rates of myocarditis or pericarditis for adolescents aged 12-17 years after either dose of the Pfizer-BioNTech primary series were 0 to 1.0 (females) and 4.8 to 6.1 (males) cases per million doses administered; the reporting rates following the second dose were 3.8 to 7.6 (females) and 45.7 to 70.2 (males) cases per million doses administered^{7,9}. Israel's safety monitoring showed that myocarditis or pericarditis for individuals aged 12-19 years after either dose were 0 (females) and 4.5 to 11.4 (males) cases per million doses administered; the reporting rates following the second dose were 5.6 to 8.6 (females) and 59.0 to 145.2 (males) cases per million doses administered¹⁰.
 - According to the Taiwan's Vaccine Adverse Event Reporting System updated as of April. 20, 2022, the reporting rates of myocarditis or pericarditis in individuals aged 12-17 years after the first dose of the Pfizer-BioNTech were 14.1 (females) and 32.6 (males) cases per million doses administered; the reporting rates following the second dose were 16.1 (females) and 142.6 (males) cases per million doses administered. In addition, the reporting rates of myocarditis or pericarditis after the first dose for those aged 18-24 years in Taiwan were 6.8 (females) and 8.4 (males) cases per million doses administered; the reporting rates following the second dose were 11.0(females) and 32.3 (males) cases per million doses administered; the reporting rates following the booster dose were 5.7(females) and 14.6(males) cases per million doses administered.
 - Reporting rates are not equivalent to actual incidence rates. Expert review and empirical clarification are required to verify the occurrence of an adverse reaction and to establish a causal link between it and vaccination.
 - **If a fever persists for more than 48 hours or your child experiences severe allergic reactions such as difficulty breathing, wheezing, vertigo, fast heartbeat, or rash, get urgent medical attention to clarify the cause. Inform the doctor of all your child 's symptoms**, when they appeared, and the date of injection as a reference for diagnosis. Suspected severe adverse reactions can be reported to the Vaccine Adverse Event Reporting System (VAERS) via your child s health care provider or local health department(<https://www.cdc.gov.tw/Categories/3-aXITBq4ggn5Hg2dveHBg>)
4. Vaccination reduces the chance of contracting COVID-19 and the likelihood of hospitalization and death. However, it is still possible to become infected with SARS-CoV-2. Vaccinated people should continue to take health precautions and follow epidemic prevention guidelines to protect themselves.
 5. After vaccination, a COVID-19 Vaccination Record will be issued. Please keep this card in a safe place. This card must be presented at the second-shot appointment. Once it is filled in with information about both vaccine doses, the card can be used as proof of vaccination.
 6. Other ingredients in this vaccine:
 - **For individuals aged 12 years and older (purple cap/BNT162b2)** : ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), Cholesterol, Potassium chloride, Potassium dihydrogen phosphate, Sodium chloride, Disodium phosphate dihydrate, Sucrose, Water for injections.
 - **For children aged 5 to 11 years (orange cap/Comirnaty)** : ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-

hexyldecanoate) (ALC-0315)2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)1,2-Distearoyl-sn-glycero-3-phos- phocholine (DSPC), Cholesterol, Trometamol, Trometamol hydrochloride, Sucrose, Water for injections.

Adverse reactions and frequency rate in the 7 days after primary series, as observed during Phase III clinical trials ^{11,12}

Adverse reactions	Frequency		
	Individuals aged 16 and older	Individuals aged 12 to 15	Individuals aged 5 to 11
Pain at injection site	84.1%	90.5%	84.3%
Fatigue	62.9%	77.5%	51.7%
Headache	55.1%	75.5%	38.2%
Muscle ache	38.3%	42.2%	17.5%
Chills	31.9%	49.2%	12.4%
Joint aches	23.6%	20.2%	7.6%
Injection Site welling	10.5%	9.2%	20.4%
Fever (>38°C)	14.2%	24.3%	8.3%

Adverse reactions from clinical trials and post-authorization experience in individuals aged 5 and up¹

Frequency	Adverse reactions
Very common (≥1/10)	Headache, Diarrhea, Arthralgia, Myalgia, Injection site pain, Fatigue, Chills, Pyrexia ^a , injection site swelling
Common (≥1/100~ <1/10)	Nausea, Vomiting, Injection site redness ^b
Uncommon (≥1/1,000~ <1/100)	Lymphadenopathy ^c , Hypersensitivity reactions (e.g. rash, pruritus, urticaria ^d , angioedema ^d), Decreased appetite, Insomnia, Hyperhidrosis, Night sweats, Lethargy, Pain in extremity ^e , Malaise, Injection site pruritus
Rare (≥1/10,000~<1/1,000)	Acute peripheral facial paralysis ^f
Very rare (<1/10,000)	Myocarditis ^g , Pericarditis ^g
Not known	Anaphylaxis, Hypersensitivity, Paraesthesia ^g , Hypoaesthesia ^g , Erythema multiforme ^g , Extensive swelling of vaccinated limb ^g ; Facial swelling ^h

- A higher frequency of pyrexia was observed after the second dose compared to the first dose.
- Injection site redness occurred at a higher frequency (very common) in children 5 to 11 years of age.
- A higher frequency of lymphadenopathy (2.8% vs. 0.4%) was observed in participants receiving a booster.
- The frequency category for urticaria and angioedema was rare.
- Refers to vaccinated arm.
- Through the clinical trial safety follow-up period to 14 November 2020, acute peripheral facial paralysis (or palsy) was reported by four participants in the COVID-19 mRNA Vaccine group. Onset was Day 37 after Dose 1 (participant did not receive Dose 2) and Days 3, 9, and 48 after Dose 2. No cases of acute peripheral facial paralysis (or palsy) were reported in the placebo group.
- Adverse reaction determined post-authorization.
- Facial swelling in vaccine recipients with a history of injection of dermatological fillers has been reported in the post-marketing phase.

Reference

- https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
- <https://www.who.int/news/item/27-10-2021-gacvs-statement-myocarditis-pericarditis-covid-19-mrna-vaccines-updated>
- <https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a>
- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#recommendations>
- USFDA Moderna COVID-19 Vaccine Health Care Provider Fact Sheet(<https://www.fda.gov/media/144637/download>)
- USFDA Review Memorandum Addendum to CBER' s review memorandum dated November 18,2021 entitled, "CBER Assessment of a booster dose of Moderna COVID-19 Vaccine (0.25 ml) administered following a primary COVID-19 immunization series in individuals 18 years of age and older"
- <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-01-05/02-COVID-Su-508.pdf>
- <https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-05-05-2022>
- <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-20/03-COVID-Klein-Shimabukuro-508.pdf>
- https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_29032022.pdf
- <https://www.fda.gov/media/153713/download>
- <https://www.fda.gov/media/153714/download>

Student(ages 5-17) Prevaccination Checklist and Consent Form for Pfizer-BioNTech COVID-19 Vaccination

City/county: _____ School name: _____

◆ I have read the COVID-19 vaccine information sheet carefully. I understand the protective efficacy, side effects, and contraindications of **Pfizer-BioNTech COVID-19 Vaccine**, as well as the precautions to take.

I consent to the vaccination of my child using **Pfizer-BioNTech COVID-19 Vaccine** as the
 First dose / Second dose of the primary series/ Booster dose (aged 12~17 years)

I do not consent.

◆ **Vaccination location (please select one)**

Your child's school Local health department/contracted medical institution



Student's name: _____ (Grade: _____ Class: _____ Roll Number: _____)

Student's national ID/resident certificate/passport number: _____

Student's date of birth (yyyy/mm/dd) : _____

Phone number : _____

Parent or guardian's name: _____

Parent or guardian's national ID/resident certificate/passport number: _____

◆ **Prevaccination self-screening**

Check list	Response of vaccine recipient	
	Yes	No
1. Have you ever had a severe allergic reaction or other severe adverse reaction to an injectable vaccine or medication?		
2. Are you currently experiencing physical discomfort (such as a fever of 38°C and above, vomiting, or difficulty breathing)?		
3. Do you have a weakened immune system, for instance, because you're on an immunosuppressive therapy?		
4. Are you currently pregnant?		

Body temperature: _____ °C

Vaccination recommended Vaccination not recommended. Reason(s): _____

Date of evaluation (yyyy/mm/dd): _____

Ten-digit code of medical institution: _____ Physician's seal: _____